top of page
.png)
OUR INGREDIENT
Structure of 'Methionyl r-Clostridium Botulinum
Polypeptide-1 Hexapeptide-40'
'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40' is developed as recombination of peptide called “MTD” (Macro-molecule Transmission Domain) that has function of skin and target cell permeation and, active protein of botulinum toxin called 'Light Chain'. 'MTD' applied to our ingredient is originated and developed from botulinum toxin 'Heavy Chain', ,which performing a cell-penatration function of botulinum toxin.
Toxin Complex
(Medical Botox Injection)
Botulinum Light Chain A
Botulinum Heavy Chain
Hemaggultinin
Non-toxin
Non-toxin Non-Hemagglutinin
Composition
Heavy chain : Nerve cell penetration
Light chain : Botulinum Efficacy Part
Hemagglutinin
Non-toxin Non-Hemagglutinin
Commercialization
1980
Example
BOTOX (Allergan, US)
MEDITOXIN (Meditox, Korea)
Not permitted to use in Cosmetic Product
Molcular weight
900KDa
Comparison if Botulinum Ingredients
Pure Toxin
(Medical Botox Injection)
Botulinum Light Chain A
Botulinum Heavy Chain
Heavy chain : Nerve cell penetration
Light chain : Botulinum Efficacy Part
1995
XEOMIN (Merz, Germany)
Not permitted to use in Cosmetic Product
150KDa
Our Ingredient
(BPMed_BoLCA_Protein)
Botulinum Light Chain A
MTD Protein
Light Chain + MTD
Botulinum Efficacy Part
Marco-molecule Transmission Domain
(Skin & Nerve cell penetration)
= Recombination of the Protein
2014
BoLCA+ (BPMed cosmetic, Korea)
The First Botulinum Ingredient on ICID
BPMed Cosmetic has Exclusivity
50KDa
Skin and Cell Penetration Technology of MTD
Platform technology to improve transdermal delivery of
'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40'
1st Action
2nd Action
Improved penetration of functional materials into stratum corneum and other skin layers by MTD.
Maximized efficacy through the delivery of 'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40' into specific targets.
Epidermis
Dermis
Subcutaneous Tissue
Muscle Layer
Cell
bottom of page